Prophylactic Administration of Recombinant Human Thrombopoietin in the Secondary Prevention of Thrombocytopenia Induced by XELOX Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Am J Ther. 2021 Apr 7;28(4):e513-e516. doi: 10.1097/MJT.0000000000001331.

Authors

Gaowa Jin¹, Yahan Wu², Zhanfei She³, Xiaoyun Ma⁴, Shuqin Deng¹, Wenjuan Wang¹, Yungaowa Wu¹, Quanfu Li¹

Affiliations

¹ Department of Medical Oncology, Ordos Central Hospital, Ordos, China.
² Department of Medical Oncology, People's Hospital of Inner Mongolia Autonomous Region, Huhhot, China.
³ Department of Abdominal Surgery, Ordos Central Hospital, Ordos, China.
⁴ Department of Medical Oncology, Chifeng Central Hospital, Chifeng, China.

PMID: 33852489
DOI: 10.1097/MJT.0000000000001331

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Capecitabine / therapeutic use
Chemotherapy, Adjuvant
Colorectal Neoplasms* / drug therapy
Fluorouracil / therapeutic use
Humans
Oxaloacetates
Recombinant Proteins / therapeutic use
Secondary Prevention
Thrombocytopenia* / chemically induced
Thrombocytopenia* / drug therapy
Thrombocytopenia* / prevention & control
Thrombopoietin / adverse effects

Substances

Oxaloacetates
Recombinant Proteins
Capecitabine
Thrombopoietin
Fluorouracil

Supplementary concepts

XELOX